Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2A5 CAR-T
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
2A5 CAR-T is an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target CD70, a member of the tumor necrosis factor (TNF) superfamily that is overexpressed in various malignancies, including renal cell carcinoma (RCC). The 2A5 construct utilizes a camelid-derived single-domain antibody (VHH or nanobody) as the antigen-binding domain, which offers potential advantages over traditional single-chain variable fragments (scFv), such as smaller size, increased stability, and potentially lower immunogenicity. Preclinical studies have demonstrated that 2A5 CAR-T cells exhibit potent cytotoxicity against CD70-positive tumor cells, high cytokine production (IFN-γ, IL-2, and TNF-α), and superior in vivo expansion and persistence compared to scFv-based CAR-T cells. This therapy is currently being investigated for its potential to treat RCC and other CD70-expressing solid and hematological tumors.
- Other names
- anti-CD70 2A5 CAR-Tanti-CD-70 2A5 CAR-Tanti-CD 70 2A5 CAR-Tnanobody-based CD70 CAR-T
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on 2A5 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2A5 CAR-T.